Appetite Stimulants in Hospice: Mirtazapine and Capromorelin Guide

Why Appetite Matters in Hospice

Appetite is one of the most visible quality-of-life parameters in hospice. A pet that eats is a pet that maintains weight, sustains the body through underlying disease, accepts medications hidden in food, and participates in the daily ritual of meals — a meaningful family connection. A pet that stops eating loses weight rapidly, becomes more vulnerable to medication side effects, and signals to the family that the trajectory has shifted.

Anorexia in hospice patients is rarely a single problem. Underlying disease drives some of it — uremia in kidney disease, pancreatitis, nausea from any cause, hepatic disease, cancer. Pain reduces appetite. Anxiety reduces appetite. Anti-emetic inadequacy reduces appetite. Cognitive dysfunction can disrupt feeding cues. The hospice vet works through the differential and treats what is treatable before reaching for appetite stimulants alone.

Appetite stimulants are bridges, not cures. They buy nutrition time during a phase where the family and vet are addressing the underlying cause or supporting the pet through a reversible decline. They are most useful when used with realistic expectations and as part of a broader comfort-care plan.

If You Are in Crisis

The first time a beloved pet refuses food is among the most distressing moments in hospice caregiving. The instinct to fix it, immediately, runs deep. If you or someone in your household is in mental-health crisis, call or text 988 (US Suicide and Crisis Lifeline) — free, confidential, 24/7. International readers: contact your local crisis line. The ASPCA Pet Loss Hotline (877-474-3310) offers free phone support for pet-grief specific anxiety.

Mirtazapine: How It Works and Who Benefits

Mirtazapine is one of the most widely used appetite stimulants in feline hospice and chronic-disease care. It was originally developed as a human antidepressant. The mechanism that makes it useful in pets — alpha-2 adrenergic antagonism combined with serotonin 5-HT3 receptor blockade — produces appetite stimulation and anti-nausea effects as predictable side effects.

Mirataz is a transdermal mirtazapine formulation labeled for cats since 2018. The transdermal route eliminates the oral-administration battle that anorectic cats often resist. The drug is applied to the inner ear pinna; the caregiver wears gloves to prevent self-absorption. Oral mirtazapine is also used in some hospice plans, sometimes for dogs (off-label, vet-directed) where transdermal options are not available.

Benefits beyond appetite stimulation: mirtazapine’s anti-nausea action complements maropitant or ondansetron in patients with concurrent nausea (see the hospice nausea management guide). Mild sedation can ease anxiety. Some cats become more affectionate on mirtazapine, which the family often welcomes during hospice.

Watch-fors: oversedation, hyperexcitability paradoxically in some cats, hypertension in sensitive patients. The hospice vet selects dose by weight, species, condition, and product. Dose decisions belong to the vet — never extrapolate or adjust without consultation.

Capromorelin: A Newer Ghrelin Agonist

Capromorelin is a ghrelin-receptor agonist — it stimulates the same hunger-signaling pathway the body uses naturally. The mechanism is more selective for appetite than mirtazapine’s broader serotonergic action.

Entyce is the canine capromorelin product, labeled in 2016 for inappetence in dogs. Elura is the feline product, labeled more recently for cats with chronic kidney disease. The cat label is newer and Elura is not yet universally available at all veterinary practices; some hospice vets order it on patient-specific request.

Capromorelin is administered orally (liquid in dogs; oral solution in cats). It is dosed by weight; the hospice vet calculates and prescribes. Onset of appetite effect is often noted within hours to a day. The drug pairs well with other comfort medications; it does not address nausea, so concurrent anti-emetic coverage is often required.

Watch-fors: hypersalivation in some cats (Elura’s most reported side effect), occasional vomiting, occasional diarrhea. The hospice vet weighs side-effect risk against the benefit of nutrition support.

Mirtazapine vs Capromorelin: How the Hospice Vet Chooses

An older comparison contrasted mirtazapine with cyproheptadine in cats; capromorelin enters the conversation as a more modern feline option. Selection considers: species (Entyce labeled for dogs, Elura labeled for cats, mirtazapine widely used in cats with established transdermal product), concurrent nausea (mirtazapine adds anti-nausea coverage), need for sedation or anxiolysis (mirtazapine adds, capromorelin does not), specific drug interactions, product availability, and cost.

Some patients receive both, sequenced or layered, when single-agent therapy is inadequate. The hospice vet may start one, evaluate response over a week or two, and add or switch as needed. The goal is sustained adequate intake, not a particular medication choice.

Cyproheptadine is an older antihistamine with appetite-stimulating side effect, sometimes still used in cats. It has largely been displaced by mirtazapine and capromorelin in modern hospice protocols but remains a vet-directed option where the newer drugs are unavailable or contraindicated.

Underlying Causes the Vet Addresses First

Before or alongside appetite stimulants, the hospice vet evaluates and addresses treatable causes. CKD-related appetite loss in cats often improves with phosphate binders, anti-emetics, and subcutaneous fluid support — the appetite stimulant adds to this rather than replacing it. Underlying vomiting from GI disease, hepatic dysfunction, or chemotherapy adjacency may identify a treatable contributor.

Pain reduces appetite — hospice pain management needs to be adequate before judging appetite-stimulant response. Nausea reduces appetite — anti-emetics like maropitant (Cerenia) and ondansetron are often layered with appetite stimulants. Constipation reduces appetite. Anxiety reduces appetite. The picture is rarely one-cause.

Practical Feeding Strategies

Appetite stimulants work best alongside feeding strategies that reduce barriers to eating. Warm food slightly (close to body temperature) to release aroma. Hand-feed small portions if the pet responds to it. Offer multiple small meals across the day rather than two large ones. Try preferred textures — paté for cats that have been on chunks-in-gravy, or vice versa.

For cats specifically, food-aversion can develop quickly if a cat is offered the same food repeatedly while feeling nauseated. The cat then associates that food with nausea and refuses it even when feeling better. Offering variety, or temporarily switching foods during nausea phases, can prevent aversion. Discuss food choices with the hospice vet — kidney-friendly or hepatic-friendly diets may be appropriate; in advanced hospice, palatability often outweighs strict therapeutic-diet adherence (vet-directed).

Quiet feeding environment helps. Separate feeding location from medication administration when possible. Some pets eat better when the family steps away; some eat better when a person sits nearby. Learn your individual pet’s preference.

When Appetite Stimulants Are Not the Answer

Appetite stimulants are not appropriate when the underlying disease has reached a point where eating no longer supports comfort. A pet in end-stage failure may stop eating as the body shuts down; forcing intake at that point through stimulation is not comfort care. The hospice vet helps the family recognize when the appropriate response shifts from “support intake” to “honor the body’s signal.”

The HHHHHMM Villalobos quality-of-life scale scores Hunger as one of seven parameters; persistent low Hunger combined with persistent low scores on other parameters reframes the conversation toward hospice-trajectory discussion rather than additional medications.

This is one of the harder conversations in hospice. The instinct to keep trying is strong. Hospice fundamentally is — not necessarily fighting disease, but managing comfort within the trajectory.

What to Expect on Side Effects

Both mirtazapine and capromorelin have generally favorable side-effect profiles when prescribed appropriately, but no medication is without risk. Mild lethargy, occasional GI upset, and occasional behavioral changes are reported. Most side effects resolve with continued use or dose adjustment by the vet.

Call the hospice vet promptly about: hypersalivation that persists, vomiting, marked sedation or marked agitation, refusal of water (different concern than refusal of food), or any new symptom appearing within a few days of starting the drug. Document what changed and when. The hospice vet adjusts dose, switches drugs, or removes the appetite stimulant from the regimen if side effects outweigh benefit.

Coordinating With the Rest of the Hospice Plan

Appetite stimulants sit alongside pain management, anti-emetics, hydration support, and mobility care. The hospice pain management framework and hospice nausea management often run concurrently. Subcutaneous fluid support may be added to address concurrent dehydration.

The family role is observation, administration, and communication. Track daily intake — even a rough estimate (“ate about half a normal meal at breakfast and a few bites at dinner”). Track weight weekly when feasible. Share this with the hospice vet at follow-up visits or by phone. Adjusting the regimen is iterative; honest tracking makes the iteration meaningful.

Frequently Asked Questions

How quickly do appetite stimulants work?

Onset varies. Capromorelin often shows appetite effect within hours to a day. Mirtazapine effect is sometimes immediate, sometimes within a few days of initiation. If no effect is seen within a few days of starting at the prescribed dose, call the hospice vet rather than self-adjusting.

Can my pet stay on appetite stimulants long-term?

Many hospice and chronic-disease pets remain on appetite stimulants for weeks to months under vet supervision. Mirtazapine and capromorelin have track records for extended use in pets. The hospice vet monitors for tolerance and side effects and adjusts as needed.

Is it cruel to give an appetite stimulant if my pet is dying?

Used appropriately, appetite stimulants improve comfort by supporting nutrition during a treatable phase. They are not appropriate when the body has reached end-stage shutdown. The hospice vet helps the family recognize when stimulants are comfort-supporting versus when they have become extending intervention beyond what serves the pet. Both phases are real.

My pet eats with the stimulant but vomits afterward — what’s happening?

Concurrent nausea is likely under-addressed. The hospice vet may add or adjust anti-emetic coverage (maropitant, ondansetron). The hospice nausea management guide walks through the options. Stacking appetite stimulant plus anti-emetic is a common, vet-directed combination.

I’m overwhelmed watching my pet’s appetite struggle — what can help?

Watching a beloved pet refuse food is among the heaviest moments in hospice. If you or someone in your household is in mental-health crisis, call or text 988 (US Suicide and Crisis Lifeline) — free, confidential, 24/7. International readers: contact your local crisis line. For pet-loss specific support, call the ASPCA Pet Loss Hotline at 877-474-3310 or find a Certified Pet Loss Professional through aplb.org.